0.230
+0.030
(15.00%)
Delayed:
9:56AM EDT
TSE
data delayed by 15 mins -
Disclaimer
Currency in CAD
| Range | 0.23 - 0.23 |
| 52 week | 0.19 - 0.64 |
| Open | 0.23 |
| Vol / Avg. | 8,513.00/15,573.00 |
| Mkt cap | 9.73M |
| P/E | - |
| Div/yield | - |
| EPS | -0.16 |
| Shares | 42.30M |
| Beta | 0.55 |
| Inst. own | - |
Events
Aug 5, 2013
Q4 2013 Lorus Therapeutics Earnings Release
Apr 10, 2013
Q3 2013 Lorus Therapeutics Earnings Release
|
|
Key stats and ratios
| Q4 (Nov '12) | 2012 | |
| Net profit margin | - | - |
| Operating margin | - | - |
| EBITD margin | - | - |
| Return on average assets | -165.42% | -446.66% |
| Return on average equity | -272.98% | - |
| Employees | 17 | - |
| Carbon Disclosure Rating | - | - |
Address
2 Meridian Road
TORONTO, ON M9W 4Z7
Canada
+1-416-7981200 (Phone)
+1-416-7982200 (Fax)
TORONTO, ON M9W 4Z7
Canada
+1-416-7981200 (Phone)
+1-416-7982200 (Fax)
Website links
External links
Discussion Group - Google Finance
Advertisement
Description
Lorus Therapeutics Inc. (Lorus) is a biopharmaceutical company. The Company is a discovery, research and clinical development-stage company with a focus on cancer drugs. The Company has an active portfolio, including small molecules (LOR-253/LOR-500) and an immunotherapy (IL-17E). Lorus has worked to establish a marketable anticancer product pipeline, with products in various stages of development ranging from discovery and pre-clinical to a product available to start a Phase III clinical trial. Lorus has one subsidiary, NuChem Pharmaceuticals Inc. (NuChem).
Officers and directors
| Jim A. Wright Ph.D. | Chairman of the Board | |
| Aiping H. Young M.D., Ph.D. | President, Chief Executive Officer, Director | |
| Elizabeth Williams | Acting Chief Financial Officer, Director - Finance | |
| Yoon Lee | Vice President - Research | |
| Herbert Abramson | Independent Director | |
| Denis R. Burger Ph.D. | Independent Director | |
| Mark D. Vincent | Independent Director | |
| Warren Whitehead | Independent Director |